Acetyl L'Carnitine may interact with anticoagulant medications
Still, it boosts the pharmaceutical company's chances of winning a slice of the booming obesity drug market, which some analysts expect to be worth more than $100 billion a year by the early 2030s
This rigorous evaluation has led to the accelerated recognition of the cardioprotective, renoprotective, and vasoprotective effects of SGLT2i ( Figure 1 )
Both medicines remain in active clinical development, with phase 2 and phase 3 trials ongoing
Combining lifestyle benefits with specialty allowances For organizations looking to go beyond standard wellness reimbursements, LSAs can integrate seamlessly with specialty allowances, niche programs, and inflation benefits
References 1.Khamis A.A., Salleh S.Z., Ab Karim M.S., Mohd Rom N.A., Janasekaran S., Idris A., Abd Rashid R.B